A meta-analysis method for identifying potential blood based protein markers associated with Alzheimer’s disease

. The Alzheimer's disease (AD) is a persistent neurodegenerative disorder characterized by loss of memory and different cognitive capabilities which represents 60 to 80% of dementia. Present day Alzheimer's remedies just treat and postpone the deterioration of dementia manifestations. A biomarker could provide a detailed measurements of brain abnormality, which can aid in the early detection of disease in people who have very mild symptoms and also the treatments targets could be developed for the disease in its early stages, before irreversible brain damage or mental decline occurs. Individuals with Alzheimer's disease and different types of dementia progress at various rates, and biomarkers may aid in predicting and monitoring their progression. Thereby researchers are looking for precise preclinical biomarkers for prognosis of cognitive impairment. The current methods that are used in AD diagnosis are expensive, invasive or time consuming. Hence there is a potential requirement for less invasive and economically feasible blood-based biomarkers to assist in large-scale screening of the geriatric population. The objective of this analysis was to evaluate the reported blood-based protein biomarkers of Alzheimer's disease (AD). A methodical PubMed survey was performed on 1195 articles distributed among 2007 and March 2018 using the key phrases "Alzheimer's infection" and "plasma biomarker" and 58 articles were chosen that met with the filtering criteria. The blood-based proteins of AD from the selected papers were scored using a meta-scoring system.In this study, 90 blood based proteins were identified, of which 15 were reported multiple times. The six highest meta scored proteins are APOE, BNP, CRP, CD40, TNF α and Clusterin. Further examinations and broad trial validations are important to affirm the clinical use of these potential biomarkers for AD diagnosis.